Stroke prevention: Antiplatelet and antithrombolytic therapy

Haemostasis

Volumn 30, Issue SUPPL. 3, 2000, Pages 14-26

  Diener, Hans Christoph ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; TICLOPIDINE;

ANTICOAGULATION; BLEEDING; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; MORTALITY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STROKE;

EID: 0034484991     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054194     Document Type: Conference Paper

References (50)

1. High-dose acetylsalicylic acid after cerebral infarction
2. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia
3. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin
4. Persantin-Aspirin in cerebral ischemia. Part II. Endpoint results
5. Secondary prevention of vascular disease by prolonged antiplatelet treatment
6. Collaborative overview of randomised trials of antiplatelet therapy - I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
7. Thrombotic thrombocytopenic purpura after stenting and ticlopidine
8. 'A.I.C.L.A.' controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia
9. A randomized trial of aspirin and sulfinpyrazone in threatened stroke
10. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
11. CAST: Randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke
12. The warfarin-aspirin symptomatic intracranial disease study
13. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. Final rule for professional labeling of aspirin, buffered aspirin and aspirin in combination with antacid drug products
14. Use of acetylsalicylic acid in the secondary prevention of stroke
15. European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
16. European stroke prevention study 2. Efficacy and safety data
17. Controversies in stroke: Past and present. The Willis lecture
18. Low-dose aspirin and stroke: 'It ain't necessarily so'
19. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
20. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: Final results of the MRC European Carotid Surgery Trial (ECST)
21. Controlled trial of aspirin in cerebral ischemia. II
22. Controlled trial of aspirin in cerebral ischemia
23. The Canadian American ticlopidine study (CATS) in thromboembolic stroke
24. Prevention des recidives des accidents vasculaires cerebraux ischemiques par les anti-agregants plaquettaires
25. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
26. Atrial fibrillation and stroke. Revisiting the dilemmas
27. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke
28. Fraxiparine in ischemic stroke study (FISS bis)
29. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke
30. Low-molecular-weight heparin for the treatment of acute ischemic stroke
31. Dipyridamole alone or combined with low dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo
32. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis
33. Platelet function and pharmacology of antiplatelet drugs
34. Thrombotic thrombocytopenic purpura related to ticlopidine
35. Aspirin as an antiplatelet drug
36. Platelet-active drugs. The relationships among dose, effectiveness, and side effects
37. Aspirin in ischemic cerebrovascular disease
38. Randomised trial of prophylactic daily aspirin in British male doctors
39. Aspirin in patients with cerebral ischemia and normal angiograms or non-surgical lesions
40. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study
41. Final report on the aspirin component of the ongoing physicians health study
42. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke
43. The European Stroke Prevention Study (ESPS). Principal end-points
44. Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischemic stroke
45. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events
46. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin
47. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results
48. Critical analysis of the combination of dipyridamole plus acetylsalicylic acid versus acetylsalicylic acid alone in the secondary prevention of stroke
49. Stroke prevention: Cardiac and carotid-related stroke
50. Vascular event rates in patients with atherosclerotic cerebrovascular disease